What is the Medical Research Future Fund?
The Medical Research Future Fund is a grant to support research projects that boost illness prevention and promote early intervention.
The Australian Government’s Medical Research Future Fund is a $20 billion investment in the health of Australians, our economy and the sustainability of our health system.
The Medical Research Future Fund (MRFF) is supporting researchers to discover the next penicillin, pacemaker, cervical cancer vaccine, or cochlear ear.
As part of the 2014-15 Budget, the Australian Government announced the establishment of the $20 billion Medical Research Future Fund (MRFF) to provide a sustainable source of funding for vital medical research over the medium to longer term.
The Medical Research Future Fund offers the opportunity to strategically fund research and address national priorities in a cohesive and coordinated way. It complements existing medical research and innovation funding to improve health outcomes by distributing new funding in more diverse ways to support stronger partnerships between researchers, healthcare professionals, governments and the community. Funding will complement the work of the National Health and Medical Research Council, the Commonwealth Science Council and the Australian Government’s National Innovation and Science Agenda, including the Biomedical Translation Fund.
Strategy and Priorities
As required by the Medical Research Future Fund Act 2015, the Australian Medical Research Advisory Board developed the inaugural Australian Medical Research and Innovation Strategy 2016-2021 and the accompanying Australian Medical Research and Innovation Priorities 2016-2018. These documents were registered with the Federal Register of Legislative Instruments on 9 November 2016 and announced by the Government on the same day.
The Strategy and Priorities have been considered by Government in deciding the first disbursements from the Medical Research Future Fund.
The key streams
- Patients – The MRFF will deliver more advanced healthcare and medical technology that will improve the health of Australians.
- Researchers – The MRFF is supporting our best health and medical researchers to make breakthrough discoveries, develop their skills and progress their careers in Australia.
- Research Missions – Missions are programs of work with ambitious objectives that are only possible through major funding, leadership and collaboration.
- Research Translation – The MRFF funds research translation – turning research discoveries into new treatments and cures.
Contributions to the Medical Research Future Fund endowment have been sourced from savings within the Health portfolio that will accumulate until the capital target of $20 billion is reached. Disbursements over the first five years of the Medical Research Future Fund are projected to be $1.4 billion, and when the fund matures it is anticipated that annual disbursements of up to $1 billion per annum.
The first disbursements from the Medical Research Future Fund focus on translating research into real health benefits, breakthrough investments in new technologies and health challenges, and enhancing Australia’s reputation for research excellence and leadership.
From 2016-17, the first disbursements from the Medical Research Future Fund will inject over $65 million into a range of programs that cut across the research pipeline – fuelling new discoveries and the translation and commercialisation of great Australian ideas.
How to apply
To apply for MRFF funding, you need to be registered with GrantConnect. By registering, you will be notified about new grants in your area of interest.
You will need to review the eligibility requirements for any MRFF program funding you are interested in applying for as each of the grants will likely have differing requirements to apply.
Medical Research Future Fund – Latest News
23 April 2022 – UNSW Academics Awarded Over $4m For Stroke And Kidney Disease Research
The Federal Government’s Medical Research Future Fund (MRFF) scheme has granted more than $4 million to two projects at UNSW Sydney’s George Institute for Global Health.
The two grants were among four projects awarded International Clinical Trial Collaborations funding, which aims to increase Australian leadership and participation in high quality international collaborative clinical trials.
A team of researchers have been awarded over $2.2 million to conduct a new trial to improve outcomes for people with advanced stages of kidney disease. Professor Craig Anderson at UNSW Medicine and Health and Director of Global Brain Health, The George Institute will receive just over $1.8 million for the trial.
21 December 2021 – Medical research gets $276m boost
Researchers working to improve the lives of people with chronic neurological conditions and brain cancer are among the scientists who may benefit from a $276.4 million injection into medical research.
The government says the funding, drawn from the $20 billion Medical Research Future Fund, will improve health outcomes for all Australians and tackle global health challenges. The new funding rounds also include grants in maternal health and chronic respiratory conditions, as well as digital innovations in primary health care.
|Recipient Name||Recipient ABN||Value (AUD)||Grant Activity|
|Monash University||12 377 614 012||$7,979,999.10||Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (CALIPSO): multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery|
|University of Melbourne||84 002 705 224||$4,909,215.00||Addressing the poor outcomes of young women with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer|
|The University of Queensland||63 942 912 684||$3,839,117.60||SWiMS – Schizophrenia Weight, Metformin and Semaglutide: A double blind double dummy placebo controlled multi-centre RCT|
|University of Melbourne||84 002 705 224||$3,686,076.20||Look before you leap: How transthoracic ECHOcardiography before fractured Neck Of Femur saves lives in frail older people â€“ the proposed Pragmatic ECHONOF III trial|
|Monash University||12 377 614 012||$3,162,379.40||Fibrinogen Early In Severe Trauma StudY II (FEISTY II)|
|Monash University||12 377 614 012||$2,970,301.10||SCANPatient: Synoptic reporting of CT scans assessing cancer of the pancreas|
|The University of Adelaide||61 249 878 937||$2,904,210.20||REMIT: An international, multi-centre, randomised clinical trial to compare Obinutuzumab + Calcineurin Inhibitor to Corticosteroid + Cyclophosphamide treatment regimens in Primary Membranous Nephropathy|
|The University of Queensland||63 942 912 684||$2,844,744.60||An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas â€“ 2: TREBL-2|
|Monash University||12 377 614 012||$2,534,432.00||REDEEM: A Randomised Controlled Trial of ECMO to Desedate, Extubate Early and Mobilise in severe acute respiratory infection|
|The University of Queensland||63 942 912 684||$2,486,489.20||The SiroSkin study: A multi-centre randomised double-blind placebo-controlled trial of 1% topical sirolimus in the chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients|
|Flinders University||65 542 596 200||$2,374,220.10||Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours: the AUS-NET Trial|
|Flinders University||65 542 596 200||$2,352,010.80||A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study)|
|The University of Newcastle||15 736 576 735||$2,107,804.40||A precision medicine clinical trial platform to BEAT CF|
|Queensland University of Technology||83 791 724 622||$2,069,492.72||Improving clinical outcomes for children and adults with bronchiectasis: a multi-centre randomised controlled trial using a novel mucolytic with a discovery biomarker|
|The University of Queensland||63 942 912 684||$2,044,955.10||Optimising Care: Phase III Trial in women with metastatic breast cancer to improve quality of life via exercise and diet|
|University of Melbourne||84 002 705 224||$2,038,621.80||Driving functional recovery after spinal cord injury using transcutaneous electrical spinal cord neuromodulation (TESCoN)|
|The University of Adelaide||61 249 878 937||$2,014,561.20||HEPATA: Hereditary Pancreatitis and AutoIslet Transplant Trials in Australia|
|University of Melbourne||84 002 705 224||$1,992,218.00||Augmenting dietary protein during critical illness: A cluster randomised cross-sectional double cross-over clinical trial|
|University of Sydney||15 211 513 464||$1,982,681.32||LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS|
|The University of Adelaide||61 249 878 937||$1,712,340.60||The AIRSPACE Trial: AntI-MRSA PhAge Cocktail treatment via Acoustic Enhanced Nebulisers|
|Monash University||12 377 614 012||$1,678,493.00||More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial|
|University of New South Wales||57 195 873 179||$1,531,130.80||Improving the lives of people with Phantom Limb Pain – the TITAN trial (graded moTor Imagery for phanTom lImb pAiN)|
|University of New South Wales||57 195 873 179||$1,515,180.00||A Platform trial of combination precision guided therapies for high risk childhood cancer|
|University of Melbourne||84 002 705 224||$1,453,336.70||Accelerating clot lysis in ischemic stroke with dornase alfa in an Umbrella Bayesian Optimised Phase 2 trial|
|University of Melbourne||84 002 705 224||$1,400,752.00||Eliminating HIV that persists on antiretroviral therapy through treatment with the BCL-2 antagonist, venetoclax|
|Murdoch Childrens Research Institute||21 006 566 972||$1,353,796.18||Is oral antibiotic treatment alone non-inferior to standard care for children with bone and joint infections?|
|Monash University||12 377 614 012||$998,608.80||INTER-EWING -1 – International clinical research program to improve outcomes in newly diagnosed Ewing Sarcoma patients – Trial 1.|
|University of New South Wales||57 195 873 179||$668,444.00||4CAST: A phase I/II study evaluating the safety and efficacy of VT-464 in combination with chemotherapy in patients with metastatic breast cancer|
|Edith Cowan University||54 361 485 361||$561,910.00||A Multicomponent Exercise Medicine Programme in Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy (the EXPAN trial): A Two-armed Phase I Randomised Controlled Trial|
|UNIVERSITY OF NEW SOUTH WALES||$9,967,326.00||Scaling up infectious disease point-of-care testing for Indigenous people.|
|THE GARVAN INSTITUTE OF MEDICAL RESEARCH||$6,455,808.70||P-OMICs-flow: Integrating precision oncology into clinical programs|
|University of Melbourne||$3,762,327.90||A Randomised Controlled Trial of MDMA-Assisted Psychotherapy for Treatment-Resistant Social Anxiety in Young Adults with Autism Spectrum Disorder|
|ST VINCENT’S INSTITUTE OF MEDICAL RESEARCH||$2,943,600.00||Pathway to use of immunotherapy in clinical practice for type 1 diabetes|
|Monash University||$2,727,173.50||Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression|
|University of Melbourne||$1,977,354.90||Dimethyltryptamine (DMT)-Assisted Psychological Therapy for Treatment-Resistant Major Depression, Alcohol Use Disorder, and Dual Diagnosis|
|University of Sydney||$1,951,246.45||A randomised, double-blind, controlled trial of MDMA-assisted exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder|
|University of Melbourne||$1,745,708.55||Clinical Trial of Cannabidiol for Treatment Resistant Anxiety Disorders in Youth|
|University of Melbourne||$1,448,343.80||Psilocybin-assisted therapy for refractory Functional Neurological Disorder|
|University of Sydney||$1,175,522.20||PANOREXIA: A clinical trial of psilocybin-assisted psychotherapy in anorexia nervosa|